SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) CTO Abhimanyu Verma sold 5,000 shares of the company's stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $8.80, for a total transaction of $44,000.00. Following the sale, the chief technology officer owned 172,171 shares in the company, valued at $1,515,104.80. The trade was a 2.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Abhimanyu Verma also recently made the following trade(s):
- On Wednesday, August 19th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.20, for a total transaction of $41,000.00.
- On Friday, August 7th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.60, for a total value of $38,000.00.
- On Tuesday, August 4th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.95, for a total value of $34,750.00.
- On Monday, July 6th, Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.10, for a total value of $26,953.50.
- On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.51, for a total value of $38,261.44.
SOPHiA GENETICS Stock Down 1.4%
SOPHiA GENETICS stock traded down $0.12 during mid-day trading on Wednesday, hitting $8.53. The company had a trading volume of 232,020 shares, compared to its average volume of 241,759. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. SOPHiA GENETICS SA has a 1 year low of $3.10 and a 1 year high of $8.85. The business has a fifty day moving average of $6.33 and a 200 day moving average of $5.37. The stock has a market cap of $715.58 million, a price-to-earnings ratio of -7.42 and a beta of 0.96.
SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. On average, sell-side analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of brokerages have recently commented on SOPH. HC Wainwright lifted their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Zacks Research upgraded SOPHiA GENETICS to a "hold" rating in a research report on Tuesday, July 21st. BTIG Research lifted their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, SOPHiA GENETICS has a consensus rating of "Hold" and an average price target of $10.00.
Read Our Latest Report on SOPH
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the business. AXQ Capital LP purchased a new position in SOPHiA GENETICS during the second quarter worth $119,000. AWM Investment Company Inc. purchased a new stake in shares of SOPHiA GENETICS in the second quarter valued at $9,809,000. Hennion & Walsh Asset Management Inc. acquired a new stake in shares of SOPHiA GENETICS during the second quarter valued at $567,000. Royal Bank of Canada boosted its stake in shares of SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company's stock valued at $96,000 after acquiring an additional 18,781 shares during the last quarter. Finally, Sei Investments Co. purchased a new stake in SOPHiA GENETICS during the 1st quarter worth about $1,772,000. 31.59% of the stock is owned by hedge funds and other institutional investors.
SOPHiA GENETICS Company Profile
(
Get Free Report)
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider SOPHiA GENETICS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SOPHiA GENETICS wasn't on the list.
While SOPHiA GENETICS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
